Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Quote | Cognition Therapeutics Inc. (NASDAQ:CGTX)
Last: | $2.37 |
---|---|
Change Percent: | -0.48% |
Open: | $2.11 |
Close: | $2.37 |
High: | $2.535 |
Low: | $2.1 |
Volume: | 2,486,959 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Cognition Therapeutics Inc. (NASDAQ:CGTX)
PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders will host an investor webcast on Monday, July 29, 2024...
PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that abstracts summarizing clinical e...
Message Board Posts | Cognition Therapeutics Inc. (NASDAQ:CGTX)
Subject | By | Source | When |
---|---|---|---|
Great! I believe we'll do quite | crudeoil24 | investorshub | 02/22/2023 2:15:32 PM |
Already been here for a few weeks lol. | tw0122 | investorshub | 02/22/2023 1:35:11 PM |
Nice "pop" on FDA phase II news! If | crudeoil24 | investorshub | 02/22/2023 1:18:23 PM |
The START study is supported by a grant | tw0122 | investorshub | 02/22/2023 1:16:02 PM |
Chart is looking better all of the time. | anderson800 | investorshub | 01/06/2023 12:29:11 PM |
News, Short Squeeze, Breakout and More Instantly...
Cognition Therapeutics Inc. Company Name:
CGTX Stock Symbol:
NASDAQ Market:
Cognition Therapeutics Inc. Website:
PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders will host an investor webcast on Monday, July 29, 2024...
PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that abstracts summarizing clinical e...
Completed enrollment for Phase 2 SEQUEL trial in mild-to-moderate Alzheimer’s disease (AD); topline results expected 2Q 2023 SHINE (AD) trial currently enrolling patients with first patient in Spain enrolled. Expect full enrollment by end of 2023 Received FDA clearance to...